Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, sickle cell disease	Recruiting	Phase 2	2026-07-27		NCT02675959

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Children's Hospital Los Angeles	90
Children's Hospital Medical Center, Cincinnati	229
Dana-Farber Cancer Institute	324
Johns Hopkins University	579
Medical College of Wisconsin	201
New York Medical College	28
University of California, Los Angeles	355
University of Florida	315

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Medical College of Wisconsin	Milwaukee	United States	483
New York Medical College	Valhalla	United States	71
University of California Los Angeles	Los Angeles	United States	87
University of Florida	Gainesville	United States	1